Chronic Pain Market, By Drug Class (Opioids, Non-steroidal anti-inflammatory drugs (NSAIDS), Anticonvulsants, Antidepressants, and Others), By Indication (Neuropathic pain, Arthritis pain, Chronic back pain, Cancer pain, Migraine, Fibromyalgia, and Others

Chronic Pain Market, By Drug Class (Opioids, Non-steroidal anti-inflammatory drugs (NSAIDS), Anticonvulsants, Antidepressants, and Others), By Indication (Neuropathic pain, Arthritis pain, Chronic back pain, Cancer pain, Migraine, Fibromyalgia, and Others), By Application (Musculoskeletal, Neuropathy, Oncology, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Chronic pain is defined as any pain lasting for more than three months or past the normal time of healing. The conditions that cause chronic pain are numerous and wide-ranging from arthritis, back pain, cancer, neurological disorders and fibromyalgia among others. Sedentary lifestyles and rising chronic diseases can increase the prevalence of chronic pain globally. It negatively impacts quality of life by limiting mobility and daily functioning. Global chronic pain market consists of drugs for pain management, neuromodulation devices, and other treatment modalities that provide relief and improve patient outcomes. Rapid growth in geriatric population who are more prone to such conditions, rise in healthcare expenditure, new product launches, and increasing awareness about management options can drive the market growth.

Market Dynamics:

Increasing prevalence of chronic diseases and injuries has significantly contributed to rising incidence of chronic pain worldwide. These include musculoskeletal disorders like osteoarthritis and lower back pain. Growing geriatric population who are more susceptible to such conditions can drive the market growth. Furthermore, greater healthcare spending, new product innovations, and ability to pay for expensive treatment options can also drive the market growth. However, presence of alternatives like generic drugs, non-compliance to medications, and side effects of certain therapies can pose challenges to market players. Moreover, regulatory hurdles for new product approvals can also hamper the market growth. Emerging economies provide major opportunities for industry players. Technological advancements in pain treatment modalities can open new avenues for the market growth.

Key features of the study:

This report provides in-depth analysis of the global chronic pain market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global chronic pain market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer, Eli Lilly, GlaxoSmithKline, Novartis, Johnson & Johnson, AstraZeneca, Purdue Pharma, Endo Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., and Mallinckrodt Pharmaceuticals

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global chronic pain market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic pain market

Detailed Segmentation-

By Drug Class Insights (Revenue, USD Bn, 2019 - 2031)

Opioids

Non-steroidal anti-inflammatory drugs (NSAIDS)

Anticonvulsants

Antidepressants

Others

By Indication Insights (Revenue, USD Bn, 2019 - 2031)

Neuropathic pain

Arthritis pain

Chronic back pain

Cancer pain

Migraine

Fibromyalgia

Others

By Application Insights (Revenue, USD Bn, 2019 - 2031)

Musculoskeletal

Neuropathy

Oncology

Others

By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Regional Insights (Revenue, USD Bn, 2019 - 2031)

North America

U.S.

Canada

Latin America

Brazil

Argentina

Mexico

Rest of Latin America

Europe

Germany

U.K.

Spain

France

Italy

Russia

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

ASEAN

Rest of Asia Pacific

Middle East

GCC Countries

Israel

Rest of Middle East

Africa

South Africa

North Africa

Central Africa

Key Players Insights

Pfizer Inc.

Johnson & Johnson

GlaxoSmithKline PLC

Bayer AG

Novartis AG

Endo Pharmaceuticals

Bristol-Myers Squibb

Eli Lilly and Company

Teva Pharmaceutical Industries Ltd.

Reckitt Benckiser Group plc

Medtronic plc

AstraZeneca PLC

Becton, Dickinson and Company

AbbVie Inc.

Horizon Therapeutics

Mallinckrodt Pharmaceuticals

Zynerba Pharmaceuticals

Neurocrine Biosciences

Sorrento Therapeutics

Cypress Pharmaceutical